Chiesi Farmaceutici SpA
76 articles about Chiesi Farmaceutici SpA
-
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
5/5/2023
Chiesi Global Rare Diseases and Protalix BioTherapeutics, Inc. announced that the European Commission has granted marketing authorization to PRX-102 in the European Union for the treatment of adult patients with Fabry disease.
-
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc
4/12/2023
Chiesi Farmaceutici S.p.A. announced the completion of the acquisition of Amryt Pharma Plc, a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases.
-
Chiesi's international growth continues
4/5/2023
Chiesi, the research-oriented international biopharmaceutical group headquartered in Parma, recorded a turnover of €2,749 billion in 2022, an increase of 13.6% from 2021.
-
Chiesi Global Rare Diseases Announces FDA Approval of Lamzede®(velmanase alfa-tycv) for Alpha-Mannosidosis
2/16/2023
Chiesi Global Rare Diseases announced that the U.S. Food and Drug Administration has approved Lamzede® for the treatment of non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients.
-
Chiesi appoints Giuseppe Accogli as new Group CEO
1/30/2023
Chiesi, the international research-focused biopharmaceutical Group, is pleased to announce Giuseppe Accogli as new Group CEO.
-
Italian biopharma Chiesi Farmaceutici SpA announced Sunday it was acquiring rare disease-focused Amryt Pharma in a deal that could reach up to $1.48 billion in value.
-
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
1/8/2023
Chiesi Farmaceutici S.p.A. and Amryt Pharma Plc announced that the companies have entered into a definitive agreement under which Chiesi will acquire Amryt.
-
Chiesi USA Sponsors ASHP Advantage Initiative to Support Pharmacy Technician Recruitment and Retention
12/2/2022
Chiesi USA, the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare group, announced its sponsorship of the ASHP Advantage initiative to support pharmacy technician recruitment and retention.
-
Chiesi USA Announces Publication of Health Economics Analysis of Selective Early Rescue Surfactant Administration vs. Standard Surfactant Administration for Premature Infants with Respiratory Distress Syndrome
11/29/2022
Chiesi USA, the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare group, announced the publication of an article describing a health economic model comparing selective early rescue surfactant administration versus standard surfactant administration for infants with respiratory distress syndrome.
-
Chiesi USA Chosen as One of Fortune’s 25 Best Small and Medium Workplaces in Biotechnology and Pharmaceuticals
10/17/2022
Chiesi USA, Inc., the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group, has been ranked No. 15 among Fortune’s 25 Best Small and Medium Workplaces in Biotechnology and Pharmaceuticals.
-
Zealand Pharma and Novo Nordisk linked resources to commercialize Zegalogue for severe hypoglycemia. For that and more from a busy week across the globe, see inside.
-
Chiesi Global Rare Diseases Announces Support for Jeffrey Modell Foundation's Global Genetic Sequencing Initiative "Jeffrey's Insights"
6/1/2022
Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research focused healthcare Group, announced that it is joining with other pharmaceutical companies to support the Jeffrey Modell Foundation's initiative, "Jeffrey's Insights," a global genetic sequencing program.
-
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Topline Results from the 24-Month Phase III BALANCE Clinical Trial of PRX-102 for the Treatment of Fabry Disease
4/4/2022
Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases announced topline results from the BALANCE pivotal Phase III clinical trial evaluating pegunigalsidase alfa, 1 mg/kg, administered every two weeks, compared to agalsidase beta for the treatment of Fabry disease.
-
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of the BRIGHT Phase III Clinical Trial Evaluating PRX-102 for the Treatment of Fabry Disease
3/18/2022
Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases announced final results from the BRIGHT Phase III clinical trial evaluating pegunigalsidase alfa for the potential treatment of Fabry disease.
-
For the United States, the total economic burden of rare disease is estimated to be $2.2 trillion per year.
-
Chiesi Global Rare Diseases Announces Results from Study Evaluating Economic Burden of Rare Diseases and Launches Second Annual #WeWearStripes Campaign on Rare Disease Day
2/28/2022
Chiesi Global Rare Diseases announced the release of a white paper titled, "The Burden of Rare Diseases: An Economic Evaluation," based on results from a study conducted with support from IQVIA, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry.
-
Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for Treatment of Fabry Disease
6/2/2021
Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthare Group, provided an update regarding the clinical development of pegunigalsidase alfa for the proposed treatment of Fabry disease.
-
Chiesi Group calls for #ActionOverWords in the fight against climate change
5/10/2021
Chiesi Group, the largest international pharmaceutical company Certified B Corporation™, reinforces 2035 carbon neutral target with #ActionOverWords campaign to encourage measurable sustainability commitments and invite accountability.
-
Chiesi Global Rare Diseases Announces FDA Approval of FERRIPROX® (deferiprone) for Treatment of Transfusional Iron Overload due to Sickle Cell Disease
5/1/2021
Chiesi Global Rare Diseases announced that the U.S. Food & Drug Administration has approved FERRIPROX® for the treatment of transfusional iron overload due to sickle cell disease or other anemias in adult and pediatric patients 3 years of age and older.
-
Chiesi USA Appoints VP of Medical Affairs to Support Continued GrowthMartin Marciniak, RPh, MPP, PhD, appointed as Vice President of Medical Affairs
3/29/2021
Chiesi USA, the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group, has appointed Martin Marciniak, RPh, MPP, PhD, as Vice President of Medical Affairs to progress the company’s therapeutic area efforts.